Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (164)	8/25/1998 1:13:00 PM
From: technetx	Read Replies (5) \| Respond to of 422

Mason, IMO, there are other reasons the ABS did not sell well in Europe: Blud didn't push it. Why? Insufficient support personnel . The company could not spread itself that thin. The last thing they wanted were unhappy customers. I know from talking with Gallup a year or so ago ,that the company was not very interested in introducing the ABS to the whole world (Asia,eg. Mideast)...reason given: support, not to mention the marketing required ( cultural and language further complications). As Gallup said "the ABS was never meant for foreign markets". Also, remember , in spite of all this, 30 ABS units were placed outside the USA over the last 1 to 2 years. Ten of which are in Canada.US market is 15x size of Canadian serology market.